Intracranial Stents Total Addressable Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The intracranial stents market sits within the broader neurovascular and implantable medical device sectors, both of which are expanding steadily as aging populations and improved diagnostics increase procedure volumes. The $15.4 billion 2025 valuation reflects demand for devices used in treating wide-necked aneurysms, intracranial atherosclerosis, and venous sinus stenosis, alongside flow diverters and related adjunct implants. Because no government statistical body publishes a dedicated TAM for this category, size estimates are drawn from corporate disclosures and broader stent-market modeling that include intracranial devices.

• •Global intracranial stents TAM estimated at $15.4 billion in 2025.
• •Trajectory is consistent with the broader stent market projected to reach $18.46 billion by 2030 at a 3.7% CAGR.
• •No national statistical agency publishes a dedicated intracranial stent TAM; figures rely on private research and company filings.

Rising prevalence of cerebrovascular disease, particularly ischemic stroke and intracranial atherosclerosis, is the principal demand driver, supported by expanded indications for flow diversion and venous sinus stenting. Technology improvements, including better deliverability, lower thrombogenicity surfaces, and imaging-compatible materials, are broadening the eligible patient pool and supporting procedure growth. Increased healthcare investment in Asia-Pacific and Latin America is also expanding addressable volumes beyond the traditional US and Western European core markets.

• •Growing stroke and cerebrovascular disease burden worldwide is increasing procedure volumes.
• •Improved delivery systems and biomaterials are expanding clinical indications and safety profiles.
• •Healthcare infrastructure expansion in emerging markets is widening the geographic patient base.

The market is commonly segmented by stent type (closed-cell, open-cell, flow diverters, and venous sinus stents), indication (aneurysm, atherosclerotic disease, idiopathic intracranial hypertension), and end user (hospitals, ambulatory surgical centers, specialty neurovascular clinics). North America currently leads on the back of high procedure reimbursement and concentrated neurointerventional expertise, while Europe maintains a strong second position with established clinical guidelines. Asia-Pacific is the fastest-growing region as China, Japan, and India scale up stroke intervention capacity and domestic device manufacturing.

• •Flow diverters and closed-cell stents are the dominant product categories by revenue share.
• •North America holds the largest regional share, with Asia-Pacific posting the highest growth rate.
• •HS code 9021 trade data captures this segment only as part of broader orthopedic and implantable device flows.

What are the recent trends and outlook?

Near-term trends point toward continued migration away from open surgical aneurysm repair toward endovascular stent-based approaches, supported by accumulating long-term clinical data. Polymer-based and bioresorbable scaffold research, alongside surface-modified metallic stents aimed at reducing in-stent thrombosis, is a notable R&D focus that could reshape competitive dynamics later in the decade. Given the 3.7% CAGR baseline and incremental indication expansion, the market is expected to track toward the high-teens in dollar terms by 2030, with growth weighted toward flow diverters and venous sinus stents.

• •Endovascular techniques continue to replace open neurosurgical approaches for suitable aneurysm cases.
• •Bioresorbable polymers and antithrombogenic surface coatings are key R&D investment areas.
• •Market is projected to approach the $18.5 billion range by 2030 at a 3.7% CAGR.